Integrated Multi-Modality Transfusion-Transmitted Disease (TTD) Testing Systems for Armed Services Blood Bank Center-Europe (ASBBC-EUR), Landstuhl Regional Medical Center (LRMC), Germany

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9406

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

6630

Additional Details
Set Aside

NONE

Place of Performance

Landstuhl, Rhineland-Palatinate, GERMANY

SourceSAM
The Defense Health Agency (DHA), under the Department of Defense, is conducting market research to identify qualified sources capable of providing a comprehensive, integrated multi-modality Transfusion-Transmitted Disease (TTD) testing solution for the Armed Services Blood Bank Center-Europe (ASBBC-EUR), located at Landstuhl Regional Medical Center (LRMC) in Landstuhl, Rhineland-Palatinate, Germany. This notice, issued as a Sources Sought/Request for Information (RFI), is intended solely for planning and market research purposes and does not constitute a solicitation for proposals or quotations. **Purpose and Scope** The primary objective of this procurement is to equip the ASBBC-EUR with a state-of-the-art, fully integrated TTD testing system that meets all U.S. Food and Drug Administration (FDA) requirements for blood-donor screening. The solution must encompass the supply, installation, validation, training, ongoing maintenance, software support and upgrades, technical support, and reagent/consumable support for three complementary testing platforms. These platforms must collectively perform the full suite of FDA-required blood-donor screening assays, including: - **Immunohematology / ABO-Rh, Syphilis, Cytomegalovirus (CMV), Antibody Titer** (e.g., Beckman Coulter PK7400 or equivalent) - **Serology** (e.g., Abbott Alinity s or equivalent) for HIV Antigen/Antibody Combo, Anti-HCV, HBsAg, HTLV I/II, Anti-HBc, and Chagas - **Nucleic Acid Testing (NAT)** (e.g., Grifols Procleix Panther / Ultrio Elite or equivalent) for HIV, HBV, HCV, West Nile Virus, and Babesia The anticipated annual testing volume is approximately 6,000 whole-blood units, with additional testing for residual plasma and platelets as needed. All systems must be FDA Center for Biologics Evaluation and Research (CBER)-cleared/licensed for blood-donor screening. While dual-marked (FDA + CE) systems are preferred, FDA-only systems are acceptable if they are compatible with German power standards (single-phase 230 V / 50 Hz) without the need for a transformer. **Key Requirements and Deliverables** The Government seeks a single integrated multi-modality solution from one prime contractor or a formal teaming arrangement. Respondents proposing a team, joint venture, or prime-subcontractor structure must clearly identify the lead entity, roles, and commercial distribution authority for each platform. If a single-source or team solution is not feasible, the Government may consider separate procurements for individual modalities. Critical site and utility constraints must be addressed, including: - **Power:** All equipment must operate on single-phase 230 V / 50 Hz power with Schuko connectors preferred. Respondents must specify continuous and peak power demands for each analyzer and supporting equipment. - **Water:** All platforms are assumed to require treated/purified water (reverse osmosis or equivalent, Clinical Laboratory Reagent Water or Type I preferred). Respondents must detail water consumption, purity specifications, daily volume, and the footprint of any required water-treatment systems. - **Footprint:** Exact dimensions, weight, and clearance requirements for all equipment and water-treatment systems must be provided. - **Environmental:** Equipment must be compatible with ambient conditions of 18–28°C and 20–80% relative humidity. - **Network & Data Infrastructure:** All data interfaces must function within the existing DoD/DHA local area network, with no external commercial internet or vendor-installed wireless networks permitted. Both lease (cost-per-test or cost-per-kit, inclusive of reagents, maintenance, and support) and outright purchase solutions will be considered, with a stated preference for leased equipment due to a potential facility relocation within the next 2–5 years (up to 50 km, typically 20 km, from the current site). Respondents should address how their solution accommodates relocation or early termination, as well as any associated costs or logistics for de-installation, transport, and re-installation. All performance will occur on a U.S. military installation in Germany under the NATO Status of Forces Agreement (SOFA), subject to both U.S. and host-nation laws and regulations. Respondents must confirm their ability to perform under these conditions and identify any in-country service capability, parts stocking locations, or technical personnel based in Germany or the European Union. Initial correlation and validation must meet both U.S./DHA and German standards, with all required reagents and consumables for this phase included in the initial setup/installation cost (not in ongoing test quantities). **Contracting Entity and Classification** - **Contracting Entity:** Defense Health Agency (DHA), Department of Defense - **Place of Performance:** Landstuhl, Rhineland-Palatinate (DE-RP), Germany - **NAICS Code:** 334516 (Analytical Laboratory Instrument Manufacturing) - **Product Service Code:** 6630 - **Set-Aside:** None specified **Contact Information** - **Primary Contact:** Cliff Roberts, [email protected], +49 6371 9464 4810 - **Secondary Contact:** Matthew Elden, [email protected] **Additional Considerations** Interested parties must have or begin obtaining active registration in the System for Award Management (SAM.gov), and are encouraged to indicate their European or NATO CAGE code status. Respondents are requested to submit a capability statement (maximum 10 pages) addressing company information, platform FDA clearance, solution integration, pricing constructs, technical and site requirements, in-country support capabilities, relevant experience, ability to meet a not-later-than operational date of 27 September 2027, and approach to ongoing maintenance and support. This RFI is open for responses until 21 October 2026. The full notice and submission instructions are available at: https://sam.gov/opp/e0cea55b66d94e5ca5f5e7513ac4a7f4/view Contractors with experience in providing integrated, FDA-cleared blood-donor screening solutions, particularly those with established support infrastructure in Europe, are encouraged to review the detailed requirements and consider responding to this market research opportunity.